Posters

Filters

Clear Filters
All Days Sun, Sep 27 Mon, Sep 28 Tue, Sep 29

Sunday, September 27

3:00 PM - 4:00 PM ET

2256 - Efficacy of Combined Chemoradiotherapy and Immunotherapy vs. Chemoradiotherapy Alone in Patients Aged 70 Years and Older With Locally Advanced or Oligometastatic Esophageal Cancer
Speaker: Wang, Yujie - Affiliated Cancer Hospital of Shandong First Medical University, Shandong Cancer Hospital and Institute, Jinan
3:00 PM - 4:00 PM ET

2258 - Are Smaller Clinical Target Volume Margins Safe In Radiotherapy for Glioblastomas and High-Grade Gliomas? A Systematic Review and Meta-Analysis
Speaker: Wisener, Nicole, MSc, BMSc - University of Ottawa, Ottawa, ON
3:00 PM - 4:00 PM ET

2259 - CBCT Based Online Adaptive Radiotherapy (oART) of Locally Advanced Rectal Cancer (LARC) - First Clinical Experience and Dosimetry Benefits: A Prospective Observational Study
Speaker: Wisniewska, Natalia, MD - Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw, -1
3:00 PM - 4:00 PM ET

2260 - Association of Changes in Circulating Immune Cells With Survival in GBM Patients Treated With Chemoradiation
Speaker: Workman, Samuel, MD - Johns Hopkins Hospital, Baltimore, MD
3:00 PM - 4:00 PM ET

2261 - Peripheral Immune Profiles at 6-12 Weeks Post-Radiation, IDH Status, and MGMT Status or Other Clinical Characteristics in GBM Patients Treated with Chemoradiation
Speaker: Workman, Samuel, MD - Johns Hopkins Hospital, Baltimore, MD
3:00 PM - 4:00 PM ET

2262 - Locally Recurrent Rectal Cancer: Is Omission of Elective Nodal Irradiation Feasible? — A Propensity Score-Matched Analysis in 186 Patients
Speaker: Wu, Feng-peng, MD - Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei
3:00 PM - 4:00 PM ET

2263 - To Explore the Efficacy and Safety of Neoadjuvant Chemoradiation Therapy in Locally Advanced Colon Cancer: A Systematic Review and Meta-Analysis
Speaker: Wu, Feng-peng, MD - Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei
3:00 PM - 4:00 PM ET

2265 - Study Protocol of Neoadjuvant Concurrent Chemoradiotherapy Combined with CAPEOX and Immune Checkpoint Inhibitors for pMMR/MSS T4NanyM0 Colon Cancer: A Phase II, Prospective, Open-Label, Multi-Center, Randomized Controlled Trial(Neo-Color study)
Speaker: Wu, Feng-peng, MD - Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei
3:00 PM - 4:00 PM ET

2266 - Hypofractionated Radiotherapy Combined with Nal-IRI + 5-FU/LV, Enlonstobart and Target Therapy in Locally Recurrent Rectal Cancer (NOVELTY-R): A Single-Arm Open-Label, Phase II Trial
Speaker: Wu, Ruiyan, MD, PhD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai
3:00 PM - 4:00 PM ET

2267 - Hypofractionated Radiotherapy Combined with Immunotherapy and Chemotherapy for Locally Recurrent Rectal Cancer (TORCH-R): A Prospective, Single-Arm, Two-Cohort, Phase II Trial
Speaker: Wu, Ruiyan, MD, PhD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai
3:00 PM - 4:00 PM ET

2268 - Definitive Chemoradiotherapy vs. Esophagectomy In Patients with Clinical T1N0M0 Esophageal Squamous Cell Carcinoma: A Multi-Center, Retrospective Study from China
Speaker: Xiang, Geng - Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an, Shaanxi
3:00 PM - 4:00 PM ET

2269 - Analysis of Brain Metastases from Esophageal Cancer in the Era of Immunotherapy: A Single-Center Retrospective Study
Speaker: Xiao, Qin - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Shenzhen, Shenzhen, Guangdong